Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.35 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | THRA | P10827 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209105 | 0.83 | PARP10 (0.40) | ACACBACACAMTNR1AMTNR1BNQO2 | |
| SCHEMBL4569120 | 0.83 | PARP10 (0.38) | KMT2AACACBACACAMTNR1AMTNR1B | |
| SCHEMBL2208238 | 0.79 | ACACB (0.49) | ACACBACACAMTNR1AMTNR1BPARP10 | |
| SCHEMBL29818771 | 0.79 | ALDH1A1 (0.37) | PARP10PARP15ALOX15F2ALDH1A1 | |
| SCHEMBL25819727 | 0.77 | PARP10 (0.41) | PARP10PARP15F2THRATHRB | |
| SCHEMBL4568839 | 0.77 | PARP15 (0.42) | CNR1CNR2PARP10PARP15F2 | |
| SCHEMBL25819702 | 0.77 | KMT2A (0.44) | KMT2AACACBACACAMEN1 | |
| SCHEMBL25819726 | 0.76 | PARP10 (0.43) | PARP10PARP15F2THRATHRB | |
| SCHEMBL2209347 | 0.74 | PARP10 (0.46) | PARP10PARP15ALOX15THRATHRB | |
| SCHEMBL2204386 | 0.74 | PARP10 (0.44) | PARP10PARP15F2THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-8981153-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8829244-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-2091955-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | Acucela, Inc. (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3008/4885ACACB 142/4885ACACA 236/4885 |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20130197096-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | KMT2A 3103/4885ACACB 139/4885ACACA 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.